Drug Profile
Etanercept biosimilar - Hanhui Pharmaceutical
Alternative Names: AnBaiNuoLatest Information Update: 17 Nov 2021
Price :
$50
*
At a glance
- Originator Hisun-Pfizer Pharmaceuticals
- Developer Hanhui Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Most Recent Events
- 31 Jan 2013 Efficacy and tolerability data from a phase III trial in Rheumatoid arthritis released by Hisun-Pfizer Pharmaceuticals
- 14 Apr 2012 Preregistration for Rheumatoid arthritis in China (SC) prior to April 2012
- 01 Jan 2012 Phase-III clinical trials in Rheumatoid arthritis in China (SC) prior to January 2012